Receptor-based antagonists of the programmed cell death 1 (PD-1) pathway
AssigneeThe Board of Trustees of the Leland Stanford Junior University
InventorsAmato J. Giaccia, Mihalis S. Kariolis, Todd A. Aguilera
Life of this patent
Estimating the term…
Abstract
Provided herein are compositions and methods for alleviating cancer or infection in a subject by administering a therapeutically effective amount of a pharmaceutical composition comprising an isolated PD-1 variant polypeptide. The PD-1 variant polypeptide can inhibit the activity of PD-1 by, for example, competitive or non-competitive inhibition of the interaction between wild-type PD-1 and one or more of its ligands, PD-L1 and PD-L2.
Claims4
An isolated PD-1 variant polypeptide, wherein the variant polypeptide lacks the PD-1 transmembrane and intracellular domains, and wherein the variant polypeptide comprises an amino acid substitution of A140V as compared to SEQ ID NO:1.
An isolated PD-1 variant polypeptide, wherein the variant polypeptide lacks the PD-1 transmembrane and intracellular domains, wherein the variant polypeptide comprises an amino acid substitution of A140V as compared to SEQ ID NO:1, and wherein the variant polypeptide provides enhanced binding to PD-L1, PD-L2, or both PD-L1 and PD-L2 as compared to SEQ ID NO:1.
Dependencies are inferred from the claim text.